Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin-Reference-Cited by-同舟云学术

Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin

Published:2012-06 Issue:6 Volume:56 Page:1276-1282
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Marcellin Patrick,Reau Nancy,Ferenci Peter,Hadziyannis Stephanos,Messinger Diethelm,Tatsch Fernando,Jensen Donald

Publisher

Elsevier BV

Subject

Hepatology

Reference30 articles.

1. American Gastroenterological Association technical review on the management of hepatitis C;Dienstag;Gastroenterology,2006

2. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C;Zeuzem;J Hepatol,2005

3. Treatment of chronic viral hepatitis;Marcellin;Baillieres Clin Gastroenterol,1994

4. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study;Jessner;Lancet,2001

5. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin;Ferenci;J Hepatol,2005

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HCV NS3Ag: a reliable and clinically useful predictor of antiviral outcomes in genotype 1b hepatitis C virus-infected patients;European Journal of Clinical Microbiology & Infectious Diseases;2016-05-13

2. Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study;PLOS ONE;2015-03-31

3. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals;BMC Infectious Diseases;2014-09

4. HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients;PLoS ONE;2014-06-19

5. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy;Journal of Infection;2014-04